When you stop 🛑 #TCZ #tocilizumab at 6 months of #Rx in #PMR RELAPSES are V high DON’T stop #Toci in PMR too Early Rapid and frequent flares #ACR24 @RheumNow @ACRheum #1698 https://t.co/IX5EJOcIY5

• https://x.com/Janetbirdope/status/1858221372205617199/photo/1

A#1692 Single cell RNA-seq identifies double-negative-2 (DN2) B-cell population ass w progressive SSc-ILD IgD- CD27- cluster is highest risk CD21 low B cells are distinct subset associated with sclerosis, pHTN DN2 B cells as potential biomarkers for SSc-ILD @RheumNow #ACR24 https://t.co/IbnOGS8C3t

• https://x.com/ericdeinmd/status/1858222523764105234/photo/1

Subgroup data from SELECT GCA, overall reinforces overall message I was curious to see pts previously treated with TCZ; wonder if that selects for refractory phenotype - seems not to be the case Take home: encouraging data, no subgroup issues #ACR24 @RheumNow Abstr#1695 https://t.co/5iCLE6T4u3

• https://x.com/EBRheum/status/1858214520612917751/photo/1
• https://x.com/EBRheum/status/1858214520612917751/photo/1
• https://x.com/EBRheum/status/1858214520612917751/photo/1

This will change my practice! #RCT #MMF + #MTX superior to #Cyclophosphamide then #Azathioprine In #Tayakasu’s #arteritis N=150 RCT ~1g BID #mycophenolate + 15mg/wk #Methotrexate Vs #cyclo ➡️100mg #azathioprine All got #glucocorticoids #ACR24 @RheumNow @ACRheum #1696 https://t.co/OpRep1vsmx

• https://x.com/Janetbirdope/status/1858215259355382099/photo/1

Which subsets of GCA pt might benefit most from upadacitinib? Sub-analysis from SELECT-GCA presented today: 💥Both relapsing and refractory disease 💥Pt w hx of PMR 💥Non-smokers 💥No hx ischemic eye dz In general, most subgroups still favor UPA @RheumNow #ACR24 Abst 1695 https://t.co/pX5hcX4TmR

• https://x.com/Dr_Brian_MD/status/1858215429992517954/photo/1

A#1690 fibroblast activation protein inhibitor (FAPI)-PET in SSc ILD Introduces FAPI quantification algorithm FAPI uptake predicts greater rate of FVC decline. Trend for DLCO, not statistically signif FAPI volume & intensity both predict accel lung decline #ACR24 @RheumNow https://t.co/YA2ptLDaMy

• https://x.com/ericdeinmd/status/1858215500691775807/photo/1
• https://x.com/ericdeinmd/status/1858215500691775807/photo/1

Sun et al. MMF+MTX vs CYC/AZA in Takayasu. Overall response rates week 28 58.1% vs 32.4%, week 52 55.4% vs 32.4%. So MMF+MTX>CYC/AZA. But I'm not sure what to do with these results. How does it compare to toc or ada? @RheumNow #ACR24 Abstr#1696 https://t.co/Jr6S2c6AKs https://t.co/L8pMFJ5hnj

• Comparison of Mycophenolate Mofetil Plus Methotrexate versus Cyclophosphamide w…
• https://x.com/RichardPAConway/status/1858216031858078047/photo/1

Safer and less relapses in #Takayasu’s #arteritis In #MTX + #MMF Vs #Cyclo ➡️ #azathioprine @RheumNow #ACRBest @ACRheum abst#1696 WOW 😮 Amazing! https://t.co/y3BDjdAa6P

• https://twitter.com/janetbirdope/status/1858215259355382099

Can we use MTX+MMF to treat active #TAK rather than CYC? ➡️MTX+MMF vs CYC/AZA over 52W MTX+MMF had: ⬆️Better efficacy in inducing & maintaining remission ❕Comparable safety to CYC/AZA ⏩This combination may prove preferable to using CYC Ab1696 #ACR24 @RheumNow https://t.co/S0A8YNk3qL

• https://x.com/DrMiniDey/status/1858218295322665117/photo/1

A#1691 Biomarkers for Rx response SSc ILD? 92 SSc-ILD pts, 19 had progressive pulm fibrosis (PPF) KL-6 - incr in PPF, decr in those w/o PPF CXCL-4 decr across cohort - non-signif trend for more w/o PPF Specifically in MMF: CRP, KL6, CXCL4 are predictive #ACR24 @RheumNow https://t.co/9fG6atcLmK

• https://x.com/ericdeinmd/status/1858218645949682030/photo/1
• https://x.com/ericdeinmd/status/1858218645949682030/photo/1
• https://x.com/ericdeinmd/status/1858218645949682030/photo/1

#Methotrexate is a dud in #PMR for benefit above #glucocorticoids ! #RCT MTX25mg/wk + Pred 15 Mg/d tapered to 0 at 1 yr vs #Prednisone + placebo same taper NO BENEFIT from #MTX #1697 #ACR24 @ACRheum @RheumNow As FYI Poster at #EULAR observed #Leflunomide better than #MTX https://t.co/RepBmOKIsA

• https://x.com/Janetbirdope/status/1858218884286804011/photo/1
• https://x.com/Janetbirdope/status/1858218884286804011/photo/1

Abstract 1686: Urinary proteomics reveals potential markers (MMP-13, M-CSF receptor, CD163, ALCAM, FOLR2) and pathways (neutrophil degranulation, ECM, tissue remodeling) involved in lupus nephritis Class II. @RheumNow #ACR24 https://t.co/kufd2zl9yc

• https://x.com/AkhilSoodMD/status/1858211500739199121/photo/1

@kekuchinad A#1689 PFT ref equations -> inequities in SSc ILD Predict FVC uses age, ht, sex & race - higher % pred values -> underdx Race-specific v neutral equations: More black pts meet trial eligibility (69/57%), immunos (56/40), lung t, (14/9) @RheumNow #ACR24 #ACRBest https://t.co/40PFmdk3Xv

• https://x.com/ericdeinmd/status/1858211728707686717/photo/1
• https://x.com/ericdeinmd/status/1858211728707686717/photo/1
• https://x.com/ericdeinmd/status/1858211728707686717/photo/1
• https://x.com/ericdeinmd/status/1858211728707686717/photo/1

Is there a less invasive approach to evaluate lupus nephritis? Abstract 1683 highlights the potential role of 68Ga-FAPI PET imaging in evaluating for lupus nephritis. FAPI uptake ↑ in pts with lupus nephritis vs HC. Correlated with IFN -α and IFN-γ pathways. @RheumNow #ACR24